Shots:
- Samsung Bioepis has entered an asset purchase agreement with Biogen to acquire its ophthalmology assets, Byooviz & Opuviz, biosimilar versions of Lucentis (ranibizumab) & Eylea (aflibercept), in the EU
- Samsung Bioepis will assume full responsibility for the commercialization of Byooviz following the transfer of rights from Biogen, effective January 2026
- Byooviz was approved by the EC in 2021 & was launched in the EU in 2023, while Opuviz received EC & MHRA’s approval in 2024 & 2025, respectively, for multiple retinal diseases, & will be launched after the expiry or revocation of Eylea’s related EU patents
Ref: Samsung Bioepis | Image: Samsung Bioepis and Biogen | Press Release
Related News:- Samsung Bioepis and Biogen Report the EC’s Approval of Opuviz (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
